M Mäurer
Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group
Ostheimer C, Dobiasch S, Arnold C, Oertel M, Haussmann J, Gauer T, Goy Y, Suess C, Ziegler S, Panje C, Baues C, Trommer M, Skripcak T, Billiet C, Thieme A, Kaul D, Mäurer M, Ebert N, Schmitt D, Krug D, Baumann R, Henkenberens C, Giordano F, Sautter L, López G, Fleischmann D, Niyazi M, Käsmann L, Medenwald D. Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlenther Onkol 2021; 197:560-561.
01.06.2021Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group
01.06.2021Strahlenther Onkol 2021; 197:560-561
Ostheimer C, Dobiasch S, Arnold C R, Oertel M, Haussmann J, Gauer T, Goy Y, Suess C, Ziegler S, Panje Cédric, Baues C, Trommer M, Skripcak T, Billiet C, Thieme A H, Kaul D, Mäurer M, Ebert N, Schmitt D, Krug D, Baumann R, Henkenberens C, Giordano F A, Sautter L, López Guerra, Fleischmann D F, Niyazi M, Käsmann L, Medenwald D
Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group
Ostheimer C, Dobiasch S, Arnold C, Oertel M, Haussmann J, Gauer T, Goy Y, Suess C, Ziegler S, Panje C, Baues C, Trommer M, Skripcak T, Billiet C, Thieme A, Kaul D, Mäurer M, Ebert N, Schmitt D, Krug D, Baumann R, Henkenberens C, Giordano F, Sautter L, López G, Fleischmann D, Niyazi M, Käsmann L, Medenwald D. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlenther Onkol 2021; 197:385-395.
07.01.2021Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group
07.01.2021Strahlenther Onkol 2021; 197:385-395
Ostheimer C, Dobiasch S, Arnold C R, Oertel M, Haussmann J, Gauer T, Goy Y, Suess C, Ziegler S, Panje Cédric, Baues C, Trommer M, Skripcak T, Billiet C, Thieme A H, Kaul D, Mäurer M, Ebert N, Schmitt D, Krug D, Baumann R, Henkenberens C, Giordano F A, Sautter L, López Guerra, Fleischmann D F, Niyazi M, Käsmann L, Medenwald D
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Mäurer M, Oude-Elberink H, Nettis E, Nast A, Metz M, Meshkova R, Mathelier-Fusade P, Magerl M, Leslie T, Larenas-Linnemann D, Kulthanan K, Rosumeck S, Saini S, Zhao Z, Werner R, Wedi B, Vestergaard C, Vena G, Toubi E, Sussman G, Staubach P, Schmid-Grendelmeier P, Sánchez-Borges M, Kocatürk E, Katelaris C, Kapp A, Canonica G, Buense Bedrikow R, Brzoza Z, Bindslev-Jensen C, Bernstein J, Ballmer-Weber B, Baker D, Abdul Latiff A, Asero R, Aberer W, Church M, Craig T, Kaplan A, Hide M, Hebert J, Grattan C, Gonçalo M, Godse K, Giménez-Arnau A, Ensina L, Dressler C, Danilycheva I, Zuberbier T. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73:1393-1414.
01.07.2018The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
01.07.2018Allergy 2018; 73:1393-1414
Mäurer M, Oude-Elberink H, Nettis E, Nast A, Metz M, Meshkova R Y, Mathelier-Fusade P, Magerl M, Leslie T A, Larenas-Linnemann D, Kulthanan K, Rosumeck S, Saini S S, Zhao Z, Werner R N, Wedi B, Vestergaard C, Vena G A, Toubi E, Sussman G, Staubach P, Schmid-Grendelmeier P, Sánchez-Borges M, Kocatürk E, Katelaris C H, Kapp A, Canonica G W, Buense Bedrikow R, Brzoza Z, Bindslev-Jensen C, Bernstein J A, Ballmer-Weber Barbara, Baker D, Abdul Latiff A H, Asero R, Aberer W, Church M K, Craig T, Kaplan A, Hide M, Hebert J, Grattan C, Gonçalo M, Godse K, Giménez-Arnau A, Ensina L F, Dressler C, Danilycheva I V, Zuberbier T
Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
Tettenborn B, Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Maschke M, Limmroth V. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17 (1):31-7.
07.06.2010Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
07.06.2010Eur J Neurol 2010; 17 (1):31-7
Tettenborn Barbara, Putzki Norman, Yaldizli Oezguer, Mäurer M, Cursiefen S, Kuckert S, Maschke M, Limmroth V
Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey
Schuetz P, Batschwaroff M, Dusemund F, Albrich W, Bürgi U, Mäurer M, Brutsche M, Huber A, Müller B. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis 2009; 29:269-77.
29.12.2009Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey
29.12.2009Eur J Clin Microbiol Infect Dis 2009; 29:269-77
Schuetz P, Batschwaroff M, Dusemund Frank, Albrich Werner, Bürgi U, Mäurer M, Brutsche M, Huber A R, Müller B
Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. European journal of neurology : the official journal of the European Federation of Neurological Societies 2009
09.07.2009Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
09.07.2009European journal of neurology : the official journal of the European Federation of Neurological Societies 2009
Putzki Norman, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn Barbara, Limmroth V